Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00861146 · ClinicalTrials.gov registry record · Phase 2
Concurrent Alcohol and Smoking Treatment: Effects on Alcohol Relapse Risk
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 151
- Enrollment target
NCT00861146: Completed Phase 2 study, sponsored by Yale University.
NCT00861146 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 151 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (14% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00861146, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 151 participants
- Enrollment target
Study Summary
The majority of individuals with alcohol problems remain current smokers, and the negative health consequences of smoking among these individuals are substantial. This study will investigate the impact of smoking cessation interventions initiated during intensive alcohol treatment on processes reflecting risk of alcohol relapse.
Primary Outcome
7-day point prevalence smoking abstinence verified by breath carbon monoxide missing coded as smoking
Interventions
- BEHAVIORAL behavioral counseling plus contingency management
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2009-04 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
What the finished NCT00861146 record still lists
NCT00861146 is an interventional study that assigns participants to a tested intervention. The registered 151 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (14% higher).
The record links to 0 conditions, and to 1 intervention - of which behavioral counseling plus contingency management is the first listed.
NCT00861146 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00861146 about?
NCT00861146 is a clinical study titled "Concurrent Alcohol and Smoking Treatment: Effects on Alcohol Relapse Risk". The majority of individuals with alcohol problems remain current smokers, and the negative health consequences of smoking among these individuals are substantial. This study will investigate the impact of smoking cessation interventions initiated during intensive alcohol treatment on processes refle...
What is the current status of trial NCT00861146?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 151 participants. The study started on 2009-04. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00861146?
The interventions under investigation include: behavioral counseling plus contingency management (BEHAVIORAL).
Who is sponsoring clinical trial NCT00861146?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00861146's enrollment target sits among peer trials
151 454th of 2000 higher than 1,546 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01409161 · 151 participants · Phase 2
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
- NCT04245397 · 151 participants · Phase 1
Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
- NCT05761223 · 151 participants · Phase 1
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
- NCT07195656 · 151 participants · NA
Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia